JAK2 Mutation Testing Strategy for Polycythemia Vera
JAK2V617F mutation testing should be the first-line molecular test performed in any patient suspected of polycythemia vera, using peripheral blood or bone marrow screening. 1
Initial Testing Algorithm
Start with JAK2V617F mutation analysis as the primary diagnostic test when evaluating suspected PV, since this mutation is present in approximately 95% of PV cases. 1, 2 This test can be performed on peripheral blood, making it accessible and non-invasive. 1
Sequential Testing Based on JAK2V617F Results
If JAK2V617F is positive: This strongly supports the diagnosis of PV and should prompt measurement of serum erythropoietin (EPO) levels, which are typically low or suppressed in PV. 3
If JAK2V617F is negative: Proceed immediately to JAK2 exon 12 mutation testing in patients with suspected PV, as exon 12 mutations account for the remaining ~5% of PV cases that are JAK2V617F-negative. 1
Complementary Diagnostic Tests
Serum erythropoietin measurement provides critical complementary information and should be obtained alongside JAK2 testing. 3, 4
- Low or suppressed EPO strongly suggests primary (clonal) erythrocytosis such as PV
- Normal or elevated EPO points toward secondary causes of erythrocytosis 3
Bone marrow biopsy is indicated when JAK2 mutation is detected or when serum EPO is low, to identify hypercellularity with pan-myelosis—a minor diagnostic criterion for PV. 3 However, bone marrow biopsy can be omitted in patients with hemoglobin >18.5 g/dL in males or >16.5 g/dL in females who are JAK2V617F-positive. 1
Diagnostic Thresholds
Confirm erythrocytosis with hemoglobin ≥18.5 g/dL in men or ≥16.5 g/dL in women on at least two separate blood draws to exclude transient hemoconcentration. 3
Important Clinical Pitfalls
Iron deficiency can mask PV by lowering hemoglobin below diagnostic thresholds; if clinical suspicion remains high despite borderline hemoglobin levels, reassess after iron repletion. 3 This is a critical pitfall that can delay diagnosis and appropriate treatment.
Secondary causes do not exclude PV. Sleep apnea and PV can coexist—in one series, 18% of erythrocytosis cases were PV, while 29% of patients with sleep apnea had concurrent PV. 3 Therefore, JAK2 testing should not be deferred pending sleep apnea evaluation when the clinical picture suggests possible PV.
Prognostic Implications of JAK2 Testing
The JAK2V617F variant allele frequency (VAF) has prognostic significance beyond diagnosis. 2, 5 Higher VAF is linked to increased risk of thrombotic complications and disease progression. 2 Arterial thrombotic events occur in approximately 16% of patients at PV diagnosis, and progression to acute leukemia occurs in ~6.8% of cases. 3
When JAK2 Testing is Unavailable
If JAK2 mutation testing is not readily available or affordable, inflammatory markers including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII) show high sensitivity and specificity (>85%) for distinguishing PV from secondary polycythemia. 6 However, these should be considered adjunctive tools rather than replacements for definitive JAK2 mutation analysis.